In summary, the initial studies of etythropoietin in anemic patients with end-stage renal disease are encouraging. Hopefully, larger, ongoing studies will provide answers to remaining questions such as blood pressure regulation, altered dialysis clearance, potential problems with arteriovenous access and the appropriate target hematocrit in these patients.
|Original language||English (US)|
|Number of pages||3|
|Journal||Journal of clinical pharmacology|
|State||Published - 1988|
ASJC Scopus subject areas
- Pharmacology (medical)